Objectives: The treatment of choice for congenital heart disease (CHD) with pulmonary arterial hypertension (PAH) is still controversial. We assessed the efficacy and safety of perioperative inhaled iloprost therapy in CHD with PAH. Methods: Among 45 patients with a ventricular septal defect and/or an atrial septal defect with PAH, 28 patients were treated with inhaled iloprost before and after surgery. Perioperative clinical parameters and plasma B-type natriuretic peptide (BNP) were evaluated. Results: No statistical difference in the estimated right ventricular systolic pressure (e-RVP), the e-RVP-to-systemic pressure ratio, and preoperative BNP levels between the iloprost group and the control group were found. Among the iloprost group, oxygen saturation was increased significantly after iloprost inhalation therapy (p = 0.0052). The iloprost group was also significantly correlated with less use of inhaled nitric oxide in the immediate postoperative period compared to the control group (p = 0.021). The durations of mechanical ventilation (p = 0.018), ICU stay (p = 0.005), and chest tube use (p = 0.039) were significantly shorter in the iloprost group compared to the control group. The plasma BNP, checked on 7th day of postoperatively, was lower in the iloprost group than in the control group (p = 0.008). Conclusion: Perioperative inhaled iloprost therapy showed the benefit of cardiac functional improvement and early weaning of postoperative supportive care in the management of CHD with PAH.

Keywords:
Congenital heart disease, Iloprost, Pulmonary arterial hypertension
1.
Tulloh RM: Congenital heart disease in relation to pulmonary hypertension in paediatric practice. Paediatr Respir Rev 2005;6:174-180.
2.
Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, Cortina J, David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones MT, Pintor PP, Salamon R, Thulin L: Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999;15:816-822, discussion 822-823.
3.
Lee JE, Hillier SC, Knoderer CA: Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med 2008;23:329-334.
4.
Baker SE, Hockman RH: Inhaled iloprost in pulmonary arterial hypertension. Ann Pharmacother 2005;39:1265-1274.
5.
Dimopoulos K, Peset A, Gatzoulis MA: Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol 2008;129:163-171.
6.
Ivy DD, Doran AK, Smith KJ, Mallory GB Jr, Beghetti M, Barst RJ, Brady D, Law Y, Parker D, Claussen L, Abman SH: Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:161-169.
7.
Opitz CF, Wensel R, Winkler J, Halank M, Bruch L, Kleber FX, Höffken G, Anker SD, Negassa A, Felix SB, Hetzer R, Ewert R: Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005;26:1895-1902.
8.
Theodoraki K, Rellia P, Thanopoulos A, Tsourelis L, Zarkalis D, Sfyrakis P, Antoniou T: Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass. Can J Anaesth 2002;49:963-967.
9.
Winterhalter M, Simon A, Fischer S, Rahe-Meyer N, Chamtzidou N, Hecker H, Zuk J, Piepenbrock S, Strüber M: Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth 2008;22:406-413.
10.
Hoeper MM, Barberà JA, Channick RN, Hassoun PM, Lang IM, Manes A, Martinez FJ, Naeije R, Olschewski H, Pepke-Zaba J, Redfield MM, Robbins IM, Souza R, Torbicki A, McGoon M: Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009;54(suppl 1):S85-S96.
11.
Beghetti M, Galiè N: Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009;53:733-740.
12.
Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, Chiossi E, Landzberg M: Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54.
13.
Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
14.
Tissot C, Beghetti M: Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag 2009;5:325-331.
15.
Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W: Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther 2004;102:139-153.
16.
Goldsmith DR, Wagstaff AJ: Inhaled iloprost: in primary pulmonary hypertension. Drugs 2004;64:763-773, discussion 774-775.
17.
Hoetzenecker K, Ankersmit HJ, Bonderman D, Hoetzenecker W, Seitelberger R, Klepetko W, Lang IM: Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: a case report. J Thorac Cardiovasc Surg 2009;137:760-761.
18.
Kim YH, Yu JJ, Yun TJ, Lee Y, Kim YB, Choi HS, Jhang WK, Shin HJ, Park JJ, Seo DM, Ko JK, Park IS: Repair of atrial septal defect with Eisenmenger syndrome after long-term sildenafil therapy. Ann Thorac Surg 2010;89:1629-1630.
19.
Lopes AA, O'Leary PW: Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease. Cardiol Young 2009;19:431-435.
20.
Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, Niedermeyer J, Fabel H, Seeger W: A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension - German PPH study group. J Am Coll Cardiol 2000;35:176-182.
21.
Rimensberger PC, Spahr-Schopfer I, Berner M, Jaeggi E, Kalangos A, Friedli B, Beghetti M: Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 2001;103:544-548.
22.
Milo-Cotter O, Cotter-Davison B, Lombardi C, Sun H, Bettari L, Bugatti S, Rund M, Metra M, Kaluski E, Kobrin I, Frey A, Rainisio M, McMurray JJ, Teerlink JR, Cotter-Davison G: Neurohormonal activation in acute heart failure: results from VERITAS. Cardiology 2011;119:96-105.
23.
Knirsch W, Häusermann E, Fasnacht M, Hersberger M, Gessler P, Bauersfeld U: Plasma B-type natriuretic peptide levels in children with heart disease. Acta Paediatr 2011;100:1213-1216.
24.
Yang D, Liu Z, Yang Z: Ghrelin and its relation with N-terminal brain natriuretic peptide, endothelin-1 and nitric oxide in patients with idiopathic pulmonary hypertension. Cardiology 2013;124:241-245.
25.
Rastogi D, Ngai P, Barst RJ, Koumbourlis AC: Lower airway obstruction, bronchial hyperresponsiveness, and primary pulmonary hypertension in children. Pediatr Pulmonol 2004;37:50-55.
26.
Winterhalter M, Antoniou T, Loukanov T: Management of adult patients with perioperative pulmonary hypertension: technical aspects and therapeutic options. Cardiology 2010;116:3-9.
27.
Gorenflo M: Perioperative care in patients with pulmonary hypertension after cardiac surgery: clinical management, outcome and future clinical research - results from an expert meeting. Cardiology 2010;116:1-2.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.